Theralase Technologies Inc.
TSX VENTURE : TLT

Theralase Technologies Inc.

February 14, 2011 09:00 ET

Theralase Appoints Chief Scientific Officer

TORONTO, ONTARIO--(Marketwire - Feb. 14, 2011) - Theralase Technologies Inc. (TSX VENTURE:TLT) announced today the appointment of Dr. Arkady Mandel as Chief Scientific Officer.

Arkady Mandel, M.D., Ph.D., DSc., earned his designation as a medical doctor from the Moscow State Medical University in 1978. His medical residency included internships in: dermatology, infectious diseases, urology and venereal diseases at the Central Research Institute of Dermatology and Venerology in 1980, followed by a Ph.D. from the same institution in 1982. Dr. Mandel was then awarded, in recognition of his scientific knowledge, original research, publications and extensive contributions to the field of clinical medicine the highest academic research degree in science, that of a Doctor of Science. Dr. Mandel's Doctor of Science accreditation majored in: biochemistry, microbiology, immunology, biophysics, and photobiology, and was awarded jointly from the Academy of Sciences and the U.S.S.R. Ministry of Public Health in 1989. Dr. Mandel is one of the key founders of the therapeutic use of lasers in dermatology and other areas of clinical medicine, as well as the originator and developer of phototherapy methods that offer numerous benefits to patients throughout the world.

Roger Dumoulin-White, President and CEO of Theralase Inc. stated that, "We are extremely fortunate to attract an accredited researcher of such a high calibre as Arkady. With over 100 original papers and scientific monographs to his name, combined with over 200 international patents attributed to his research, Dr. Mandel is not only an esteemed medical professional and an internationally respected scientist, but also an experienced executive manager of research and development teams dedicated to the field of biotechnology and drug development. We look forward to working with Arkady to lead the research and development of our core technologies through to commercialization; specifically, our patented photo dynamic technology platform for the treatment of cancer and eradication of bacteria and viruses, as well as our patented super-pulsed biofeedback laser technology used for the treatmentof inflammation and pain in numerous medical conditions.

Visit the corporate or regulatory website at www.theralase.com or www.sedar.com for more information.

About Theralase Technologies Inc.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is designed to specifically target and destroy cancers, bacteria and viruses.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward- looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Contact Information